PMID- 16951139
OWN - NLM
STAT- MEDLINE
DCOM- 20071126
LR  - 20220331
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Linking)
VI  - 66
IP  - 17
DP  - 2006 Sep 1
TI  - TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of 
      prostate cancer.
PG  - 8337-41
AB  - Prostate cancer is a common and clinically heterogeneous disease with marked 
      variability in progression. The recent identification of gene fusions of the 
      5'-untranslated region of TMPRSS2 (21q22.3) with the ETS transcription factor 
      family members, either ERG (21q22.2), ETV1 (7p21.2), or ETV4 (17q21), suggests a 
      mechanism for overexpression of the ETS genes in the majority of prostate 
      cancers. In the current study using fluorescence in situ hybridization (FISH), we 
      identified the TMPRSS2:ERG rearrangements in 49.2% of 118 primary prostate 
      cancers and 41.2% of 18 hormone-naive lymph node metastases. The FISH assay 
      detected intronic deletions between ERG and TMPRSS2 resulting in TMPRSS2:ERG 
      fusion in 60.3% (35 of 58) of the primary TMPRSS2:ERG prostate cancers and 42.9% 
      (3 of 7) of the TMPRSS2:ERG hormone-naive lymph node metastases. A significant 
      association was observed between TMPRSS2:ERG rearranged tumors through deletions 
      and higher tumor stage and the presence of metastatic disease involving pelvic 
      lymph nodes. Using 100K oligonucleotide single nucleotide polymorphism arrays, a 
      homogeneous deletion site between ERG and TMPRSS2 on chromosome 21q22.2-3 was 
      identified with two distinct subclasses distinguished by the start point of the 
      deletion at either 38.765 or 38.911 Mb. This study confirms that TMPRSS2:ERG is 
      fused in approximately half of the prostate cancers through deletion of genomic 
      DNA between ERG and TMPRSS2. The deletion as cause of TMPRSS2:ERG fusion is 
      associated with clinical features for prostate cancer progression compared with 
      tumors that lack the TMPRSS2:ERG rearrangement.
FAU - Perner, Sven
AU  - Perner S
AD  - Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 
      EBRC 442A, 221 Longwood Avenue, Boston, MA 02115-6110, USA.
FAU - Demichelis, Francesca
AU  - Demichelis F
FAU - Beroukhim, Rameen
AU  - Beroukhim R
FAU - Schmidt, Folke H
AU  - Schmidt FH
FAU - Mosquera, Juan-Miguel
AU  - Mosquera JM
FAU - Setlur, Sunita
AU  - Setlur S
FAU - Tchinda, Joelle
AU  - Tchinda J
FAU - Tomlins, Scott A
AU  - Tomlins SA
FAU - Hofer, Matthias D
AU  - Hofer MD
FAU - Pienta, Kenneth G
AU  - Pienta KG
FAU - Kuefer, Rainer
AU  - Kuefer R
FAU - Vessella, Robert
AU  - Vessella R
FAU - Sun, Xiao-Wei
AU  - Sun XW
FAU - Meyerson, Matthew
AU  - Meyerson M
FAU - Lee, Charles
AU  - Lee C
FAU - Sellers, William R
AU  - Sellers WR
FAU - Chinnaiyan, Arul M
AU  - Chinnaiyan AM
FAU - Rubin, Mark A
AU  - Rubin MA
LA  - eng
GR  - R01AG21404/AG/NIA NIH HHS/United States
GR  - R01CA109038/CA/NCI NIH HHS/United States
GR  - T32 CA009172/CA/NCI NIH HHS/United States
GR  - P50 CA69568/CA/NCI NIH HHS/United States
GR  - P50 CA097186/CA/NCI NIH HHS/United States
GR  - P50 CA090381/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (5' Untranslated Regions)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
SB  - IM
MH  - 5' Untranslated Regions
MH  - Cell Line, Tumor
MH  - *Gene Deletion
MH  - Humans
MH  - Male
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Single Nucleotide
MH  - Prostatic Neoplasms/*genetics
MH  - Transcription, Genetic
EDAT- 2006/09/05 09:00
MHDA- 2007/12/06 09:00
CRDT- 2006/09/05 09:00
PHST- 2006/09/05 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2006/09/05 09:00 [entrez]
AID - 66/17/8337 [pii]
AID - 10.1158/0008-5472.CAN-06-1482 [doi]
PST - ppublish
SO  - Cancer Res. 2006 Sep 1;66(17):8337-41. doi: 10.1158/0008-5472.CAN-06-1482.